Table 2.
Survival estimates by treatment-related factors of 83 registered osteosarcoma patients with primary multi-systemic metastases.
| Overall Survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients | % | 1-Year | 2-Year | 5-Year | ||||||
| Rate | SE | Rate | SE | Rate | SE | p * | ||||
| Resection of the primary tumour | ||||||||||
| None or macroscopically incomplete | 43 | 55 | 0.326 | 0.071 | 0.051 | 0.035 | 0.026 | 0.025 | <0.001 | |
| Macroscopically complete, microscopically incomplete | 3 | 4 | 1.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
| Microscopically complete | 32 | 41 | 0.775 | 0.075 | 0.495 | 0.093 | 0.152 | 0.069 | ||
| Unknown | 5 | |||||||||
| Response to first-line chemotherapy † | ||||||||||
| Good (grades 1–3) | 11 | 42 | 1.000 | 0.727 | 0.134 | 0.364 | 0.145 | 0.044 | ||
| Poor (grades 4–6) | 15 | 58 | 0.786 | 0.110 | 0.397 | 0.136 | 0.000 | 0.000 | ||
| Unknown/primary or no tumour resection | 57 | |||||||||
| Macroscopically complete resection of all metastases | ||||||||||
| No | 72 | 89 | 0.481 | 0.059 | 0.135 | 0.042 | 0.068 | 0.032 | 0.001 | |
| Yes | 9 | 11 | 1.000 | 1.000 | 0.250 | 0.153 | ||||
| Unknown | 2 | |||||||||
| Macroscopically complete resection of all pulmonary metastases | ||||||||||
| No | 68 | 87 | 0.450 | 0.061 | 0.111 | 0.041 | 0.056 | 0.030 | <0.001 | |
| Yes | 10 | 13 | 1.000 | 1.000 | 0.222 | 0.139 | ||||
| No pulmonary metastases/unknown | 5 | |||||||||
| Macroscopically complete resection of all bone metastases | ||||||||||
| No | 57 | 86 | 0.424 | 0.065 | 0.129 | 0.046 | 0.064 | 0.035 | 0.062 | |
| Yes | 9 | 14 | 0.778 | 0.139 | 0.519 | 0.176 | 0.130 | 0.121 | ||
| No bone metastases/unknown | 17 | |||||||||
| Macroscopically complete resection of all other metastases | ||||||||||
| No | 25 | 68 | 0.400 | 0.098 | 0.040 | 0.039 | 0.000 | 0.000 | <0.001 | |
| Yes | 12 | 32 | 1.000 | 0.900 | 0.095 | 0.450 | 0.166 | |||
| No other metastases/unknown | 36 | |||||||||
| Radiotherapy | ||||||||||
| No | 46 | 63 | 0.478 | 0.074 | 0.205 | 0.061 | 0.046 | 0.031 | 0.352 | |
| Yes | 27 | 37 | 0.593 | 0.095 | 0.244 | 0.085 | 0.163 | 0.074 | ||
| Unknown | 10 | |||||||||
| Therapeutic radioactive medication | ||||||||||
| No | 63 | 88 | 0.551 | 0.063 | 0.273 | 0.058 | 0.109 | 0.042 | 0.011 | |
| Yes | 9 | 13 | 0.222 | 0.139 | 0.000 | 0.000 | 0.000 | 0.000 | ||
| Unknown | 11 | |||||||||
| Duration until start of chemotherapy, days | ||||||||||
| <21 | 57 | 69 | 0.500 | 0.067 | 0.206 | 0.055 | 0.056 | 0.031 | 0.289 | |
| ≥21 | 26 | 31 | 0.636 | 0.097 | 0.300 | 0.099 | 0.180 | 0.089 | ||
| Tumour progression under first-line treatment | ||||||||||
| No | 18 | 27 | 0.941 | 0.057 | 0.627 | 0.121 | 0.314 | 0.116 | <0.001 | |
| Yes | 48 | 73 | 0.396 | 0.071 | 0.090 | 0.043 | 0.000 | 0.000 | ||
| Unknown | 17 | |||||||||
* p-value, log-rank test. † According to Salzer-Kuntschik et al. [16].